from concepts to biomarkers

& innovations in precision medicine

19 research teams,

10 platforms, 2 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»

News

SEMINAIRE EXTERNE MERCREDI 12 FEVRIER

Yohei SHIMONOFujita Medical UniversitySchool of medecine, Department of Biochemistry, Nagoya (Japan) "Vicious Adipocytes : promoters of cancer stem cell properties and tumor progression"host : Andrei Turtoi (IRCM)
En savoir plus

SEMINAIRE EXTERNE IGF/IRCM

Géraldine GENTRICEquipe "Stress et Cancer"Unité CHIP (U830) - Institut Curie-Paris"Role of metabolic reprogramming in cell plasticity upon chemotherapy in ovarian cancers"hôte : Julie Pannequin (IGF)
En savoir plus

CALL FOR NEW GROUP LEADERS @ IRCM

The IRCM is recruiting new group leaders to establish world-class research programs withinan interactive and supportive scientific environment. Applicants demonstrating potentialsynergies with IRCM’s main research topics will be considered for starting an independentteam as soon as January 2027. Projects at the interface of fundamental and clinical research,particularly those focused on the ICM's flagship pathologies, will be given carefulconsideration. We welcome senior team leaders with permanent INSERM / CNRS positionsas well as early-career researchers eligible to ERC, INSERM ATIP-AVENIR and FRM start-upgrants. MORE INFORMATIONS HERE
En savoir plus

SEMINAIRE EXTERNE IRCM

Raphael J. MorscherPediatric Cancer Metabolism Laboratory, Children's Research Center,University of Zurich, 8032 Zurich, Suisse"Reprogramming neuroblastoma translation by diet-enhanced polyamine depletion"hôte : Alexandre DAVID (IRCM)
En savoir plus

Ingénieur.e d'études en techniques biologiques

Publié le 24/05/2024Mission principale :Dans le cadre de l’étude sur l’épigénétique des neutrophiles, la personne recrutée aura pour principale mission la gestion et l’analyse des prélèvements des patients atteints de cancer du poumon traités à l’ICM ou au CHU. Date de prise de fonction 01.09.2024 Durée (CDD et détachements) CDD : 18 mois Renouvelable En savoir plus ...
En savoir plus

the word of the director

"Together, let's push the limits."

"In barely 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has succeeded in raising its research to the highest international level in the field of fundamental and applied cancer research, carried out in close collaboration with the clinical departments of the Montpellier Cancer Center (ICM: l'Institut du Cancer de Montpellier), and industrial partners. Under the joint supervision of Inserm, the ICM and the University of Montpellier, the IRCM brings together more than 240 people, researchers, clinicians, technicians and students, organized in 16 research teams that rely on high-performance technical platforms and competent support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead. To do so, we will continue to structure cancer research in Montpellier, to seek excellence and to accelerate innovation and transfer to the patient in order to ultimately contribute to overcoming the countless different forms of cancer. Together, let's push the limits"

Nathalie Bonnefoy, Director of the IRCM

the word of the director

MAIN PUBLICATIONS

Tabet I, Candiello E, Fenou L, Velazquez C, Jacot W, Ribeyre C, Sardet C, Theillet C Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe.. Cancer Research. 2025;in press.

Di Michele M, Attina A, Roux P-F, Laguesse S, Florido J, Houdeville M, Choquet A, Encislai B, Arena G, De Blasio C, Wendling O, Frenois F-X, Papon L, Stuani L, Fuentes M, Jahannault Talignani C, Rousseau M, Guégan J, Buscail Y, Dupré P, Michaud H-A, Rodier G, Bellvert F, Kulyk H, Ferraro Peyret C, Mathieu H, Close P, Rapino F, Chaveroux C, Pirot N, Rubio L, Torro A, Sorg T, Ango F, Hirtz C, Compan V, Lebigot E, Legati A, Ghezzi D, Nguyen L, David A, Sardet C, Lacroix M, Le Cam L E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development. Nat Commun. 2025;16(1):67. doi:10.1038/s41467-024-55444-y

Slaninová V, Heron-Milhavet L, Robin M, Jeanson L, Aissanou A, Kantar D, Tosi D, Bréhélin L, Gongora C, Djiane A The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC Cancer. 2024;24(1):587. doi:10.1186/s12885-024-12316-4

Bruciamacchie M, Garambois V, Vie N, Bessede T, Michaud H-A, Gros L, Bonnefoy N, Robin M, Brager D, Bigot K, Evrard A, Pourquier P, Colinge J, Mathonnet M, Belhabib I, Jean C, Bousquet C, Colombo P-E, Jarlier M, Gongora C, Larbouret C ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Br J Cancer. 2024-11-29. doi:10.1038/s41416-024-02904-3

Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz L, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau M-C, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. J Immunother Cancer. 2024;12(1):e007135. doi:10.1136/jitc-2023-007135

Manteaux G, Amsel A, Riquier-Morcant B, Prieto Romero J, Gayte L, Fourneaux B, Larroque M, Gruel N, Quignot C, Jacq S, Pomiès P, Sengenes C, Chibon F, Heuillet M, Bellvert F, Watson S, Firmin N, Riscal R, Linares L A metabolic crosstalk between liposarcoma and muscle sustains tumor growth. Nat Commun. 2024;15(1):7940. doi:10.1038/s41467-024-51827-3

Villemin J-P, Bassaganyas L, Pourquier D, Boissière F, Cabello-Aguilar S, Crapez E, Tanos R, Cornillot E, Turtoi A, Colinge J Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR. Nucleic Acids Res. 2023-05-05. doi:10.1093/nar/gkad352

Jacquier V, Gitenay D, Fritsch S, Bonnet S, Gy?rffy B, Jalaguier S, Linares L, Cavaillès V, Teyssier C RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53. Cell Mol Life Sci. 2022;79(5):270. doi:10.1007/s00018-022-04277-3

Pisareva E, Mihalovi?ová L, Pastor B, Kudriavtsev A, Mirandola A, Mazard T, Maus U, Ostermann L, Weinmann-Menke J, Neuberger E, Simon P, Thierry A Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA. Genome Med. 2022;14(1):135. doi:10.1186/s13073-022-01125-8

du Manoir S, Delpech H, Orsetti B, Jacot W, Pirot N, Noel J, Colombo P-E, Sardet C, Theillet C In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. J Pathol. 2022;257(3):367-378. doi:10.1002/path.5896

Chiavarina B, Costanza B, Ronca R, Blomme A, Rezzola S, Chiodelli P, Giguelay A, Belthier G, Doumont G, Van Simaeys G, Lacroix S, Yokobori T, Erkhem-Ochir B, Balaguer P, Fabbrizio E, Di Valentin E, Detry O, Jerusalem G, Goldman S, Delvenne P, Bellahcène A, Pannequin J, Castronovo V, Turtoi A Metastatic colorectal cancer cells maintain the TGF? program and use TGFBI to fuel angiogenesis. Theranostics. 2021;11(4):1626-1640. doi:10.7150/thno.51507

Relier S, Ripoll J, Guillorit H, Amalric A, Achour C, Boissière F, Vialaret J, Attina A, Debart F, Choquet A, Macari F, Marchand V, Motorin Y, Samalin E, Vasseur J-J, Pannequin J, Aguilo F, Lopez-Crapez E, Hirtz C, Rivals E, Bastide A, David A FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell. Nat Commun. 2021;12(1):1716. doi:10.1038/s41467-021-21758-4

Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Huesgen P, Overall C, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021;11(13):6173-6192. doi:10.7150/thno.58254

Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget J-P The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020;34(5):1315-1328. doi:10.1038/s41375-019-0677-4

Alame M, Cornillot E, Cacheux V, Tosato G, Four M, Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Martineau V, Colinge J The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics. 2020;10(10):4383-4394. doi:10.7150/thno.42986

Cissé M, Pyrdziak S, Firmin N, Gayte L, Heuillet M, Bellvert F, Fuentes M, Delpech H, Riscal R, Arena G, Chibon F, Le Gellec S, Maran-Gonzalez A, Chateau M-C, Theillet C, Portais J-C, Le Cam L, Linares L Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Transl Med. 2020;12(547):eaay2163. doi:10.1126/scitranslmed.aay2163

Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Landas E, Bleuse J-P, Chardès T, Prost J-F, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br J Cancer. 2020;122(3):397-404. doi:10.1038/s41416-019-0670-8

Hamyeh M, Bernex F, Larive R, Naldi A, Urbach S, Simony-Lafontaine J, Puech C, Bakhache W, Coopman P, Hendriks W, Freiss G PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics. 2020;10(3):1016-1032. doi:10.7150/thno.38537

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest. 2020;130(2):612-624. doi:10.1172/JCI126896

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés